GLS and neoplasm: This suggests pre‐chemotherapy metabolic priming could sensitise MS_2 tumours: preclinical studies demonstrate that inhibiting glycolytic enzymes (e.g., HK2) or glutaminase restores NADPH pools and enhances doxorubicin response.